Data-driven computational analysis and simulation identified drug repurposing opportunities for COVID-19
Computational Biology, Network-based algorithms and Artificial Neural Network to predict the repositioning of 200 already approved drugs against SARS-CoV-2.
We are confident our approach has identified potential targets, since 20% of these drugs are currently in COVID-19 clinical trials. We present the mechanism of action of the 200 drugs and demonstrate the efficacy of two of these (Proguanil and Sulfasalazine) in cellular assays. This huge dataset of SARS-CoV-2 induced pathways, already approved drugs to target them, along with their mechanism of action, defines a resource for repurposing of drugs against COVID-19, either in monotherapies or in combination therapy.
About the speaker:
Namshik Han is the Head of Artificial Intelligence research group at the Milner Therapeutics Institute in University of Cambridge. He is leading the group and has responsibilities to develop and deliver the Milner’s computational biology and AI strategy. The main aim of the group is to develop and apply cutting-edge computational methods, such as artificial intelligence and machine learning, fulfilling the global mission of identifying new or better therapies from the analysis of biological data.